Effect of Pregabalin in Patients With Radiotherapy-related Neuropathic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

January 31, 2017

Conditions
Neuropathic Pain
Interventions
DRUG

Pregabalin

At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.

DRUG

Placebo

At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.

Trial Locations (4)

510060

Cancer Center of Sun Yat-sen University, Guangzhou

510120

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

510450

Guangzhou Huiai Hospital, Guangzhou

511300

Zengcheng People's Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT01869569 - Effect of Pregabalin in Patients With Radiotherapy-related Neuropathic Pain | Biotech Hunter | Biotech Hunter